Invesco Ltd. Buys New Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Invesco Ltd. bought a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 247,977 shares of the company's stock, valued at approximately $3,814,000. Invesco Ltd. owned 0.90% of ClearPoint Neuro at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CLPT. Barclays PLC boosted its position in ClearPoint Neuro by 24.3% in the 3rd quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after buying an additional 1,109 shares during the period. LPL Financial LLC boosted its holdings in shares of ClearPoint Neuro by 4.5% in the fourth quarter. LPL Financial LLC now owns 40,250 shares of the company's stock valued at $619,000 after purchasing an additional 1,750 shares during the period. R Squared Ltd bought a new position in ClearPoint Neuro in the fourth quarter worth approximately $32,000. Parsons Capital Management Inc. RI increased its holdings in ClearPoint Neuro by 1.9% during the 4th quarter. Parsons Capital Management Inc. RI now owns 141,573 shares of the company's stock worth $2,177,000 after purchasing an additional 2,600 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock worth $110,000 after purchasing an additional 3,612 shares during the period. Institutional investors own 30.08% of the company's stock.

ClearPoint Neuro Stock Performance

CLPT stock traded up $0.19 during trading on Friday, reaching $14.10. 50,706 shares of the company traded hands, compared to its average volume of 224,552. The business has a 50 day simple moving average of $12.97 and a 200 day simple moving average of $14.15. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22. The company has a market capitalization of $394.52 million, a price-to-earnings ratio of -20.43 and a beta of 0.97.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.05). The firm had revenue of $7.77 million during the quarter, compared to the consensus estimate of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. As a group, research analysts forecast that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CLPT. Lake Street Capital increased their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a research report on Tuesday, January 21st. Stifel Nicolaus raised their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Finally, B. Riley upped their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.